Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Exposure-response analysis of tivozanib in renal cell cancer treatment

Bradley McGregor • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Nivolumab Tivozanib
TiNivo-2

Bradley McGregor, MD, Dana-Farber Cancer Institute, Boston, MA, explores the efficacy and safety exposure-response analysis of tivozanib in renal cell cancer, integrating data from the TiNivo-2 trial (NCT04987203). The analysis demonstrated that tivozanib 1.34 mg offers greater antitumor activity, with comparable hypertension incidence across doses. Adding nivolumab did not improve progression-free survival or tumor size reduction. The findings emphasize the importance of optimal tivozanib dosing to maximize clinical benefit without increased safety risks. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bradley McGregor

Activation of the STRIKE trial: pembrolizumab and tivozanib in RCC
1:03
Activation of the STRIKE trial: pembrolizumab and tivozanib in RCC
Bradley McGregor • 13 Feb 2025
2025 updates of the DAD-IO trial in treatment-naïve urothelial carcinoma
1:21
2025 updates of the DAD-IO trial in treatment-naïve urothelial carcinoma
Bradley McGregor • 13 Feb 2025
ARC-20: casdatifan monotherapy in pre-treated clear cell renal cell carcinoma
2:15
ARC-20: casdatifan monotherapy in pre-treated clear cell renal cell carcinoma
Bradley McGregor • 13 Feb 2025
Sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer
4:21
Sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer
Bradley McGregor • 22 Oct 2023

Related Videos

Advances in next-generation PSMA-targeted radioligand therapy
2:09
Advances in next-generation PSMA-targeted radioligand therapy
Jeremie Calais • 1 Jun 2026
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
2:22
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
Jeremie Calais • 1 Jun 2026
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
The content of VJOncology is intended for healthcare professionals